Nebenwirkungen · Zolsketil pegylated liposomal
ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-146367 · Präparat HOS-099502
Cardiac toxicity An increased incidence of congestive heart failure is associated with doxorubicin therapy at cumulative lifetime doses > 450 mg/m2 or at lower doses for patientswith cardiac risk factors. Endomyocardial biopsies on nine of ten AIDS-KS patients receiving cumulative doses of doxorubicin pegylated liposomal greater than 460 mg/m2 indicate no evidence of anthracycline-induced cardiomyopathy. The recommended dose of doxorubicin pegylated liposomal for AIDS-KS patients is 20 mg/m2 every two-to-three weeks. The cumulative dose at which cardiotoxicity would become a concern for these AIDS-KS patients (> 400 mg/m2) would require more than 20 courses of doxorubicin pegylated liposomal therapy over 40 to 60 weeks.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-16T15:10:00Z · SHA-256 749f25cb02ef3c2557fff9c44c8608815445daccd9aad038fce4e840c7fa1845 · Passage a6091deaaee4edb990f45515696bdb78594e40fc3ee266a1e5560a28dbd6e1fe · Zeichen 14307–15036 im Abschnitt